NAMODENOSON



NAME OF DRUG : NAMODENOSON

ALSO KNOWN AS : NAMODENOSON

LABORATORY : CANFITE

STATUS AND ADVANCEMENT

Type of drug : A3AR Agonist

Clinical trials advancement : Recruiting Phase 2a

Estimated time to market : 121 months.

LABORATORY ABSTRACT ON THE DRUG

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug. In Can-Fite's pre-clinical and clinical studies, Namodenoson has demonstrated a robust anti-tumor effect via deregulation of the Wnt signaling pathway, resulting in apoptosis of liver cancer cells. Based on preclinical data showing Namodenoson has strong liver protective properties, Can-Fite intends to initiate a Phase II study in NASH. Can-Fite has received Orphan Drug Designation for Namodenoson in Europe and the U.S., as well as Fast Track Status in the U.S. as a second line treatment for hepatocellular carcinoma.

RECENT NEWS ON NAMODENOSON

2018-02-28 : Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson

2017-06-02 : New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017

2017-05-03 : Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH

2017-01-09 : Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017

SOME PUBLICATIONS RELATED WITH NAMODENOSON

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH NAMODENOSON


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE